Concordance studies of a web based system in teledermatology

Carlos Ruiz, BME¹, Claudia Gaviria, MD², Miguel Gaitán, MD², Rubén Manrique, PhD(c)³, Ángela Zuluaga, MD⁴, Andrés Trujillo, MD, MBA⁵

SUMMARY

Introduction: Implementation of teledermatology in primary care offers the possibility of treating patients using specific dermatologic knowledge in far away places with infrequent availability to these services. It is a priority to implement teledermatology services which demonstrate diagnostic reliability and satisfaction among users.

Objectives and methods: To measure the diagnostic reliability of an asynchronous teledermatology web based application by means of intraobserver and interobserver concordance during teleconsultation and traditional presential («face to face») consultation. Furthermore, to evaluate user satisfaction regarding the teleconsultation and the web application.

Results: A sample of 82 patients with 172 dermatologic diagnoses was obtained, in which an intraobserver concordance between 80.8% and 86.6%, and an interobserver concordance between 77.3% and 79.6% were found. Satisfaction was evaluated to be on an average of 92.5%.

Conclusions: The teleconsultation reliability in teledermatology is evidenced to be high, and is susceptible of improvement through the implementation of health information standards and digital dermatologic photography protocols.

Keywords: Telemedicine; Teledermatology; Diagnostic concordance; Satisfaction.

Estudios de concordancia de un sistema web de teledermatología

RESUMEN

Introducción: La implementación de la teledermatología en el cuidado primario ofrece la posibilidad de tratar pacientes utilizando conocimiento dermatológico específico desde lugares remotos que no poseen estos servicios con frecuencia. Es prioritario implementar servicios de teledermatología que demuestran fiabilidad diagnóstica y satisfacción entre todos los usuarios.

Objetivo y métodos: Medir la fiabilidad diagnóstica de una aplicación web de tele-dermatología asíncrona a través de la concordancia intra-observador e inter-observador, durante la tele-consulta y la consulta presencial. Además, evaluar la satisfacción de los usuarios con respecto a la tele-consulta y aplicación Web.

Resultados: Se obtuvo una muestra de 82 pacientes con 172 diagnósticos dermatológicos, donde se presentó una concordancia intra-observador entre 80.8% y 86.6%, por su lado la concordancia inter-observador varió entre 77.3% y 79.6%. La satisfacción alcanzó un promedio de 92.5%.

Conclusiones: Se evidencia que la fiabilidad de la tele-consulta en tele-dermatología es alta, susceptible de mejorar a través de la implementación de estándares de información en salud y protocolos de fotografía dermatológica digital.

Palabras clave: Telemedicina; Teledermatología; Concordancia diagnóstica; Satisfacción.

^{1.} Research Group in Biomedical Engineering (GIBEC), Escuela de Ingeniería de Antioquia (EIA), Universidad CES. Researcher TELEDERMA Project (Colciencias-EIA-CES). e-mail: cruiz@eia.edu.co

^{2.} Resident in Dermatology, Universidad CES, Medellín, Colombia. e-mail: cgaviriav@hotmail.com miguegaitan@yahoo.com

^{3.} Research Department Director, Universidad CES, Medellín, Colombia. e-mail: rmanrique@ces.edu.co

^{4.} Research Group in Dermatology. Co-researcher TELEDERMA Project (Colciencias-EIA-CES), Universidad CES, Medellín, Colombia. e-mail: azuluaga@une.net.co

Director, Instituto Colombiano de Medicina Tropical, Coordinator Biomedical Engineering Program EIA-CES. TELEDERMA, Project Director (Colciencias-EIA-CES). e-mail: atrujillo@ces.edu.co Received for publication noviembre 26, 2008 Accepted for publication July 1, 2009

Our society is continuously influenced by diverse emergent communication and information technologies (CITs)¹. Among these, innovative CITs for health care service outstand, supplying vital tools for health care providers who find themselves under constant pressure to offer efficient and high quality services. This pressure is due primarily to an aging population, legal suits, high patient expectations, increasing clinical costs and a decrease in the number full time available specialists².

One of the tools with a meaningful impact is telemedicine. According to the World Health Organization (WHO), telemedicine is: «providing health care services, in which distance is a critical factor, by professionals who appeal to technologies in information and communication with the objective of exchanging data to make diagnoses, find suitable treatments and prevent diseases and wounds, as well as for continuing education of health care professionals, aiming towards health improvement of the people and the communities they live in»³. Its application to diverse medical specialties has given rise to the continuous development of teleradiology, telepsychiatry, telecardiology, telepathology, teleobstetrics and telesurgery, among the most important⁴. However, it is in the field of dermatology where special development has taken place, having that the skin is an accessible organ to be observed and described, easing the diagnosis through images taken and analyzed in geographically distant places to the patient's location⁵.

The implementation of teledermatology in primary care offers the possibility of treating patients using specific dermatologic knowledge without the traditional «face to face» consultation. Additionally, remissions are decreased, access is improved, dermatological resources are optimized, waiting lists are shortened and implicit costs due to travel and the human resources involved are reduced^{6,7}. The development of teledermatology consultations, or generally denominated teleconsultations (applicable to all telemedical specialties), is performed either between patients and health care professionals or between the latter. Communication between the healthcare professional and the patient can develop directly o via third parties, being real time communication, denominated synchronic, and through «store and forward» communication, denominated asynchronically, being the latter the most common⁸.

Dermatology teleconsultations in real time process clinical information through sophisticated communi-

cation technologies such as videoconferences, which allow for gathering of complete clinical information and more control in the examination, diagnoses and immediate treatment emission for the patient. Its main disadvantages lie on the infrastructural high costs, longer consult time and low flexibility for system user's⁹. The «store and forward» teleconsultation directly transmit the clinical information and digital images via modem or Internet to a computational server with operational low costs¹⁰. These teleconsultations offer greater comfort and flexibility to the dermatologist who may answer these at the moment and place desired. A general consensus exists among diverse experts in the field of teledermatology that suggests that «store and forward» teleconsultations will turn into the standard for healthcare service in dermatology via telemedicine (Telemedicine Position Statement, developed by the group of experts in telemedicine of the American Academy of Dermatology)⁹.

Several studies with the objective of exploring the reliability of teledermatology have compared the concordance or coincidence between the «face to face» and teledermatologic diagnosis with both synchronous and asynchronous teleconsultation methodologies. The diagnoses are obtained between two or more examiners (interobserver concordance), or by only one examiner (intraobserver concordance). Little information has been found with respect to diagnostic accuracy in tele-dermatology¹¹. The countries which possess most development in teledermatology are¹²: United States, Australia¹⁰ and England¹³, among others. Recently, publications have been produced in Holland¹², Turkey¹², México⁵, Colombia¹⁴ and Spain¹⁵.

With the objective of having teledermatology accepted as an appropriate service, acceptance and satisfaction of all the involved parties must be equally evaluated. Diverse studies and reviews of this issue have evaluated patient satisfaction with «store and forward» systems. Williams *et al.*¹² reported a 93% patient satisfaction with respect to the teleconsultation. Weinstock *et al.*¹² reported that 75% of the patients interviewed would recommend the teledermatology service to other people. Likewise, Whited¹¹ presents a review of three additional studies that complete the results mentioned. According to these three studies, 42% prefer teledermatology; total satisfaction is of 4.56 over 5 according to Kvedar *et al.* and of 7.4 over 10 according to Akker *et al.*, which suggests high satisfaction with teledermatology among patients. Lastly, Collins *et al.*¹⁶ present percentages of 81 and 84 related to satisfaction about the dermatologists' opinion and following treatment, respectively.

The results obtained in the present study under the «store and forward» methodology were analyzed with the purpose of evaluating concordance between the telediagnosis and «face to face» diagnosis given by the same observer (using the web application of teledermatology and in direct contact with the patient). The concordance between the diagnosis given by a teleexpert observer and a dermatologist using the web application of teledermatology and a direct contact with the patient (interobserver) were also evaluated. With respect to the technical performance of the teledermatology application, the participating physicians evaluated speed, stability and coordination. Lastly, the patient satisfaction with respect to the teleconsultation was assessed.

MATERIALS AND METHODS

The Web application developed allows dermatologic consultation assessment at a distance, and the management of all the relevant information through databases. The system operates with two user's roles, the consulting physician and the advising physician (teleexpert). The consulting physician develops the teleconsultation by introducing the relevant information of the consultation along with images of the patient's lesions. Afterwards, the assessment of the teleexpert is required, who, at a distance, observes the information of the teleconsultation and advises in the diagnosis and treatment to follow. The logic of the application is based on the PHP programming language, using MySQL as database management system where the patient information and respective dermatologic images reside. The application is executed by the Web IIS (Internet Information Services Microsoft) V. 6.0 under a PD platform with a Windows 2003 Server operative system.

The medical team was made up of two medical residents in dermatology (R1), a dermatologist (tele-expert) with more than a 10-year experience and 3 dermatologists with more than a 5-year experience.

The study was performed in the CES Sabaneta Dermatologic Center (Centro Dermatológico del CES, Sabaneta) and in the Colombian Institute for Tropical Medicine [Instituto Colombiano de Medicina Tropical (ICMT), Antioquia], where the dermatologic consultations with professionals from the Dermatologic Center took place once a month. There were no exclusion criteria for which all patients who agreed to participate in the study were considered. For this, an informed consent protocol was developed which the patient signed after being read and receiving more information about the general objective of the study. The involved medical staff was previously trained in the use of the Web application, the use of the digital camera Sony CSC-R1 and the teleconsultation protocol.

The trials went on for 3 months, the size of the sample referred to the total amount of consultations performed in the Centro CES Sabaneta and in the municipality of Apartadó during these months in specific days. An infinite population was not considered having that disease might differ among institutions and localities.

The medical residents in dermatology, who entered the patient's basic information, chief complaint, review of systems and physical examination information in the system, evaluated the patients. The patients were then photographed obtaining images in JPEG format with a 1296x864 resolution and a color depth of 24 bits/pixel. The images were loaded in the system and the complete information was sent to the teleexpert who was in other office at the time. The latter reviewed the information and emitted a telediagnosis. The teleexpert then attended the office where the patient was present and emitted a «face to face» diagnosis. Given that the dermatologists participating in the teleconsultation also performed the «face to face» consultation within 5 minutes of the former and vice versa, total blinding of the physicians to avoid interobserver bias was not possible. For this reason, a blinding strategy model was used that did not allow the participant to know the diagnosis yielded by others. Given that between the «face to face» consultation and the teleconsultation there was no more than 5 minutes difference, the objectiveness and ethical criteria of each observer to give their diagnosis without allowing for influence from the previous diagnosis were relied on.

At the end of the teleconsultation, the medical resident in charge of entering the information in the system and the teleexpert dermatologist completed the questionnaires corresponding to the technical evaluation of the system. This evaluation measures the speed, stability and coordination variables within the consultation. In turn, the patient completed the teleconsultation satisfaction questionnaire. This evaluation measures the information understanding, consult quality, and time duration variables.

The criteria for disease concordance were in perfect agreement between the given diagnoses, with the exception of acne and melanocytic nevus, in which, given the similarity in their clinical names, a partial concordance was allowed for. Non-related diagnoses, or those not considered in the differential diagnosis, were categorized as «No information» («Sin Dato»-SD) and analyzed within the general sample.

A database was constructed in which each entry characterized a diagnosis and contained the results independently of each observer for each one of the consultation methods. The data were analyzed with Epidat Version 3.1 to obtain the intra and inter observer concordance proportions with their respective confidence intervals of 95%.

RESULTS

A total of 83 patients with 171 dermatologic diseases, with only one entry as normal skin, with 55 women and 28 men in an age range of 3 months to 67 years were evaluated. The dermatologic conditions were categorized according to the ICD-10 and the Health Sciences Descriptors (Descriptores en Ciencias de la Salud DeCS)²⁵. The studied entities are shown in their corresponding categories in Table 1.

Of the 172 clinical entries, diverse samples were taken according to the level of concordance and the information submitted in the electronic and physical clinical records. In Table 2 the concordance modalities obtained in the study are shown.

The Kappa index was not obtained for all the diagnoses, given that at least one diagnosis was present for all patients, and there were no NEGATIVE patients, which suggested a Kappa concordance analysis for each category in which more than 20 diagnoses were analyzed. In Table 3 the concordance levels are observed by category.

Of the 83 patients treated by means of the teleconsultation, a total of 73 interviews about service satisfaction were obtained (87.9%). The evaluation of each variable was carried out by indicators in which 5 is excellent and 1 is deficient. Results are shown in Table 4.

Of the 83 teleconsultations performed, a total of 75 interviews were fully carried out (90.4%) by the medical

resident. The evaluation of each variable was performed by means of indicators in which 5 is excellent and 1 is deficient. The results are shown in Table 5.

Of the 83 teleconsultations, a total of 55 completely fulfilled questionnaires were obtained (66.3%) by the teleexpert. The evaluation of each variable was performed by means of indicators in which 5 is excellent and 1 is deficient. The results are shown in Table 6.

DISCUSSION

The concordance studies in teledermatology possess diverse qualities and methodologies. In our case, the approach was to evaluate the diagnostic reliability, not precision, of an asynchronous teledermatology system. For this reason we mainly referred to the systematic review results of studies II and III by Eminovic *et al.*¹² to discuss our results. Additionally, new studies excluded by temporality are analyzed in this article.

In the present study, 5 concordance values were obtained, according to the diagnoses of the teleexpert and the control dermatologist. The percentages of the CIO₁ and CIO₂ were of 86.6% and 80.8%, respectively. These concurrence percentages are in agreement with the original and review articles in which these values range between 31% and 93%^{9,11,12}. Even though the intraobserver concordance is usually greater than the interobserver concordance, the concordance value range for complete diagnoses (31%-88%) is similar to those in studies that evaluate interobserver concordance. In our case these values were high, mainly for diseases related to adnexa, dermatitis or eczema. This suggests that the images are photographically reliable with clinical benefit, being susceptible of improvement through protocol implementation of digital medical photography. With respect to interobserver concordance, the diagnostic concordance (C O1T, C O1P-O2T) between the teleconsultation and the «face to face» consultation was of 79.6% and 77.3%, respectively. These values are similar to those published between 1999 and 2008^{5,10,12,18-21}, in which absolute concordance values between diagnoses range from 35% to 100%. It must be underscored that these diverse studies possess different epidemiologic approaches, where the reliability of the teledermatologic diagnosis of pigmented tumors, skin cancer, pigmented lesions and chronic ulcers, among the most important, are evidenced. Furthermore, they provide enough

 Table 1

 Disease categories, described disease (standard disease), case number

B35 Dermatophytosis Onichomycosis (Tinea unguium) (1) Tinea pedis (2) 3 B37 Candidiasis Candidia Onichomycosis (Candidiasis of the skin and nails) 1 B00-B09 Viral infections characterized by skin and mucous membrane lesions 1 B00-B09 Viral infections characterized by skin and mucous membrane lesions 1 B00-B09 Viral infections characterized by skin and mucous membrane lesions 1 B00-B09 Viral infections characterized by skin and mucous membrane lesions 1 B00-B09 Viral infections characterized by skin and mucous membrane lesions 1 B00-B09 Viral infections characterized by skin and mucous membrane lesions 1 B85-B89 Podiculosis, acariasis and other infestations Scables 1 C84 Peripheral and cutaneous T-cell lymphomas Mycosis fungoides (Mycosis fungoides) 2 D00-D09 in situ neoplasms Lentigo maligna (Melanoma <i>in situ</i> , unspecified site) (4) 11 1 D10-D36 Benign neoplasms (Melanocytic naevi, unspecified site) (4) 11 1 D10-D36 Idencytic naevi (Melanocytic naevi, unspecified site) (3) Verrucous naevi (Melanocytic naevi unspecified site) (1) D22 Melanocytic naevi of kinoncytic naevi unspecified site) (1) Blue naevi (Melanocytic naevi unspecified site) (1) 3 E70-Disorders o	B35-B49 Mycoses		
B37 Candidiasis Candidial Onichomycosis (Candidiasis of the skin and nails) 1 B00-B09 Viral infections characterized by skin and mucous membrane lesions 1 B85-B89 Pediculosis, acariasis and other infestations 5 cabies 1 B86-B89 Pediculosis, acariasis and other infestations 5 cabies 1 B86 Scabies S cabies 1 C81-C96 Malignant neoplasms of lymphoid, haematopoletic and related tissue 2 C84 Peripheral and cutaneous T-cell lymphomas Mycosis fungoides (Mycosis fungoides) 2 D00-D09 In situ neoplasms Lentigo maligna (Melanoma <i>in situ</i> unspecified site) (4) 11 1 D10-D36 Benign neoplasms (Melanocytic naevi, unspecified site) (4) 11 1 D22 Melanocytic naevi (Melanocytic naevi, unspecified site) (1) 1 D10-D36 Benign neoplasms Verrucous naevi (Melanocytic naevi, unspecified site) (1) 1 D22 Melanocytic naevi (Melanocytic naevi, unspecified site) (1) 1 D10-D36 Benign neoplasms Verrucous naevi (Melanocytic naevi, unspecified site) (1) 1 D22 Melanocytic naevi unspecified site) (1) 1 1 D10-D36 Benign neoplasms Sebaceous hyperplasia (Benign skin tumor, unspecified site) (1) 3 <	B35 Dermatophytosis	Onichomycosis (Tinea unguium) (1)	
(Candidiasis of the skin and nails)1B00 Eczema herpeticum (herpes simplex)Herpes simplex1B85-B89 Pediculosis, acariasis and other infestationsB86 ScabiesScabies1C31-C36 Malignant neoplasms of lymphoid, haematopoietic and related tissueC34-Peripheral and cutaneous T-cell lymphomasMycosis fungoides (Mycosis fungoides)2D00-D09 In situ neoplasmsD03 Melanoma <i>in situ</i> Lentigo maligna (Melanoma <i>in situ</i> , unspecified)1D10-D36 Benign neoplasmsD22 Melanocytic naevi(Melanocytic naevi(Melanocytic naevinaevi, unspecified site) (3)Verrucous naevi (Melanocytic naevinaevi, unspecified site) (2)Hypochromic naevi (Melanocytic naevinaevi, unspecified site) (1)BU23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (1)BU23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (1		Tinea pedis (2)	3
B00-B09 Viral Infections characterized by skin and mucous membrane lesions Herpes simplex 1 B00 Eczema herpeticum (herpes simplex) Herpes simplex 1 B85-B39 Pediculosis, acariasis and other infestations Scabies 1 C84 - C96 Malignant neoplasms of lymphoid, haematopoietic and related tissue C84 Peripheral and cutaneous T-cell lymphomas Mycosis fungoides (Mycosis fungoides) 2 D00-D09 In situ neoplasms User the state of	B37 Candidiasis	Candidial Onichomycosis	
B00 Eczema herpeticum (herpes simplex) Herpes simplex 1 B85 B30 Pediculosis, acariasis and other infestations Scabies 1 B86 Scabies Scabies 1 C81-C96 Malignant neoplasms of lymphoid, haematopoietic and related tissue Wycosis fungoides (Mycosis fungoides) 2 D00-D09 In situ neoplasms Mycosis fungoides (Mycosis fungoides) 1 D10-D36 Benign neoplasms Lentigo maligna (Melanoma in situ, unspecified) 1 D10-D36 Benign neoplasms (Melanocytic naevi, unspecified site) (4) 11 1 Intradermal naevi (Melanocytic naevi, unspecified site) (3) Verrucous naevi (Melanocytic naevi, unspecified site) (3) Verrucous naevi (Melanocytic naevi, unspecified site) (2) Hypochromic naeus (Melanocytic naevi) naevi, unspecified site) (1) 1 D23 Other benign neoplasms of skin Sebaceous hyperplasia (Benign skin tumor, unspecified site) (1) 3 E70-E90 Metabolic disorders E 1 E70 Disorders of aromatic amino-acid metabolism Ochronosis (Disorders of tyrosine metabolism) 1 E73 Disorders of lipoprotein metabolism and other Xanthelasmas (Mixed hyperlipidemia) 1 Ipidaemias Latoret unduce disorders 1 E13 Other bullous disorders		(Candidiasis of the skin and nails)	1
B85-B89 Pediculosis, acariasis and other infestations Scabies 1 C81-C96 Malignant neoplasms of lymphoid, haematopoietic and related tissue C84 Peripheral and cutaneous T-cell lymphomas Mycosis fungoides (Mycosis fungoides) 2 D00-D09 In situ neoplasms Mycosis fungoides (Mycosis fungoides) 1 1 D10-D36 Benign neoplasms Lentigo maligna (Melanoma <i>in situ</i> unspecified) 1 D10-D36 Benign neoplasms (Melanocytic naevi, unspecified site) (4) 11 Intradermal naevi (Melanocytic naevi, unspecified site) (3) Verrucous naevi (Melanocytic naevi, unspecified site) (2) Hypochromic naevi (Melanocytic naevi, unspecified site) (1) Blue naevi (Melanocytic naevi, unspecified site) (1) D23 Other benign neoplasms of skin Sebaceous hyperplasia (Benign skin tumor, unspecified site) (1) D23 Other benign neoplasms of skin Sebaceous hyperplasia (Benign skin tumor, unspecified site) (1) D23 Other benign neoplasms of skin Sebaceous hyperplasia (Benign skin tumor, unspecified site) (1) D23 Other benign neoplasms of skin Ochronosis (Disorders of tyrosine metabolism and other tabolism and other tabolism) E70 Disorders of lipoprotein metabolism and other lipidaemias Disorders of tyrosine metabolism and other tabolism and other tabolis disorders L10-L14 Bullous disorders Dermatitis herpetiformis 1 L20 Atopic dermatitis and eczema	B00-B09 Viral infections characterized by skin and mucou	s membrane lesions	
B86 Scabies Scabies 1 C81-C96 Malignant neoplasms of lymphoid, haematopoletic and related tissue Keen control (Control (Contro)))))	B00 Eczema herpeticum (herpes simplex)	Herpes simplex	1
C81-C96 Malignant neoplasms of lymphoid, haematopoietic and related tissue C84 Peripheral and cutaneous T-cell lymphomas Mycosis fungoides (Mycosis fungoides) 2 D00-D09 In situ neoplasms Lentigo maligna (Melanoma <i>in situ</i> , unspecified) 1 D10-D36 Benign neoplasms Lentigo maligna (Melanoma <i>in situ</i> , unspecified) 1 D10-D36 Benign neoplasms (Melanocytic naevi, unspecified site) (4) 11 11 Intradermal naevi (Melanocytic naevi, unspecified site) (3) Verrucous naevi (Melanocytic naevi, unspecified site) (3) Verrucous naevi (Melanocytic naevi, unspecified site) (2) Hypochromic naevi, unspecified site) (1) Blue naevi (Melanocytic naevi unspecified site) (1) 1 D23 Other benign neoplasms of skin Sebaceous hyperplasia (Benign skin tumor, unspecified site) (2) 1 D23 Other benign neoplasms of skin Sebaceous hyperplasia (Benign skin tumor, unspecified site) (1) 3 E70-E90 Metabolic disorders E70 Disorders of aromatic amino-acid metabolism Ochronosis (Disorders of tyrosine metabolism) 1 E78 Disorders of lipoprotein metabolism and other lipidaemias Latellous disorders 1 L10-L14 Bullous disorders Dermatitis herpetiformis 1 L20-L30 Dermatitis and eczema L20 Atopic dermatitis (Atopic dermatitis, unspecified) (1) 3 <td>B85-B89 Pediculosis, acariasis and other infestations</td> <td></td> <td></td>	B85-B89 Pediculosis, acariasis and other infestations		
C84 Peripheral and cutaneous T-cell lymphomas Mycosis fungoides (Mycosis fungoides) 2 D00-D09 In situ neoplasms Lentigo maligna (Melanoma <i>in situ</i> , unspecified) D10-D36 Benign neoplasms 1 D22 Melanocytic naevi (Melanocytic naevi, unspecified site) (4) 11 Intradermal naevi (Melanocytic naevi, unspecified site) (3) Verrucous naevi (Melanocytic naevi, unspecified site) (3) Verrucous naevi (Melanocytic naevi, unspecified site) (2) Hypochromic naevi (Melanocytic naevi, unspecified site) (1) Blue naevi (Melanocytic naevi unspecified site) (1) Blue naevi (Melanocytic naevi unspecified site) (1) D23 Other benign neoplasms of skin Sebaceous hyperplasia (Benign skin tumor, unspecified site) (2) Dermatofibrome (Benign skin tumor, unspecified site) (1) 3 E70-E90 Metabolic disorders E E70 Disorders of aromatic amino-acid metabolism Ochronosis (Disorders of tyrosine metabolism) and other lipidaemias L13 Other bullous disorders Dermatitis herpetiformis 1 L20-L30 Dermatitis and eczema L20-L30 Dermatitis (Atopic dermatitis, unspecified) (1) L20 Atopic dermatitis Seborrheic dermatitis (5) 3	B86 Scabies	Scabies	1
D00-D09 In situ neoplasms Lentigo maligna (Melanoma <i>in situ</i> , unspecified) D10-D36 Benign neoplasms (Melanocytic naevi, unspecified site) (4) 11 D122 Melanocytic naevi (Melanocytic naevi, unspecified site) (4) 11 Intradermal naevi (Melanocytic naevi, unspecified site) (3) Verruccus naevi (Melanocytic naevi, unspecified site) (2) Hypochromic naevi (Melanocytic naevi, unspecified site) (1) Blue naevi (Melanocytic naevi, unspecified site) (1) D23 Other benign neoplasms of skin Sebaceous hyperplasia (Benign skin tumor, unspecified site) (2) D23 Other benign neoplasms of skin Sebaceous hyperplasia (Benign skin tumor, unspecified site) (1) D23 Other benign neoplasms of skin Sebaceous hyperplasia (Benign skin tumor, unspecified site) (1) D24 Disorders of aromatic amino-acid metabolism Ochronosis (Disorders of tyrosine metabolism) E70 Disorders of lipoprotein metabolism and other Xanthelasmas (Mixed hyperlipidemia) Ipidaemias 1 L10-L14 Bullous disorders Dermatitis herpetiformis 1 L20-L30 Dermatitis and eczema Atopic dermatitis, (Atopic dermatitis, unspecified) (1) Eczema (Other atopic dermatitis, (2) L21 Seborrheic dermatitis Seborrheic dermatitis (5) 3	C81-C96 Malignant neoplasms of lymphoid, haematopoiet	ic and related tissue	
D03 Melanoma in situ Lentigo maligna (Melanoma in situ, unspecified) 1 D10-D36 Benign neoplasms (Melanocytic naevi, unspecified site) (4) 11 D22 Melanocytic naevi (Melanocytic naevi, unspecified site) (3) Verrucous naevi (Melanocytic naevi, unspecified site) (3) Verrucous naevi (Melanocytic naevi, unspecified site) (2) Hypochromic naevi (Melanocytic naevi, unspecified site) (1) Blue naevi (Melanocytic naevi unspecified site) (1) D23 Other benign neoplasms of skin Sebaceous hyperplasia (Benign skin tumor, unspecified site) (1) D23 Other benign neoplasms of skin Sebaceous hyperplasia (Benign skin tumor, unspecified site) (1) D23 Other benign neoplasms of skin Sebaceous hyperplasia (Benign skin tumor, unspecified site) (1) D23 Other benign neoplasms of skin Sebaceous hyperplasia (Benign skin tumor, unspecified site) (1) D23 Other benign neoplasms of skin Sebaceous hyperplasia (Benign skin tumor, unspecified site) (1) D23 Other benign neoplasms of skin Sebaceous hyperplasia (Benign skin tumor, unspecified site) (1) Tero-E90 Metabolic disorders Tero-E90 Metabolic disorders E70 Disorders of aromatic amino-acid metabolism Ochronosis (Disorders of tyrosine metabolism) L10-L14 Bullous disorders Tero-L14 Bullous disorders L13 Other bullous disorders Dermatitis herpetiformis <td< td=""><td>C84 Peripheral and cutaneous T-cell lymphomas</td><td>Mycosis fungoides (Mycosis fungoides)</td><td>2</td></td<>	C84 Peripheral and cutaneous T-cell lymphomas	Mycosis fungoides (Mycosis fungoides)	2
unspecified)1D10-D36 Benign neoplasmsD22 Melanocytic naevi(Melanocytic naevi, unspecified site) (4) 11 Intradermal naevi (Melanocytic naevi, unspecified site) (3) Verrucous naevi (Melanocytic naevi, unspecified site) (2) 	D00-D09 In situ neoplasms		
D10-D36 Benign neoplasmsD22 Melanocytic naevi(Melanocytic naevi, unspecified site) (4) 11 Intradermal naevi (Melanocytic naevi, unspecified site) (3) Verrucous naevi (Melanocytic naevi, unspecified site) (2) Hypochromic naevi (Melanocytic naevi, unspecified site) (1) Blue naevi (Melanocytic naevi unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (2) Dermatofibrome (Benign skin tumor, unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (2) Dermatofibrome (Benign skin tumor, unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (2) Dermatofibrome (Benign skin tumor, unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (1) 3E70 Disorders of aromatic amino-acid metabolismOchronosis (Disorders of tyrosine metabolism)E78 Disorders of lipoprotein metabolism and other lipidaemiasXanthelasmas (Mixed hyperlipidemia)L10-L14 Bullous disordersDermatitis herpetiformisL13 Other bullous disordersDermatitis (Atopic dermatitis, unspecified) (1) Eczema (Other atopic dermatitis, (2)L20 Atopic dermatitisSeborrheic dermatitis (5)	D03 Melanoma in situ	Lentigo maligna (Melanoma <i>in situ</i> ,	
D22 Melanocytic naevi(Melanocytic naevi, unspecified site) (4) 11 Intradermal naevi (Melanocytic naevi, unspecified site) (3) Verrucous naevi (Melanocytic naevi, unspecified site) (2) Hypochromic naevi (Melanocytic naevi, unspecified site) (1) Blue naevi (Melanocytic naevi unspecified site) (1) Blue naevi (Melanocytic naevi unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (2) Dermatofibrome (Benign skin tumor, unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (2) Dermatofibrome (Benign skin tumor, unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (2) Dermatofibrome (Benign skin tumor, unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (1) 3E70 Disorders of aromatic amino-acid metabolismOchronosis (Disorders of tyrosine metabolism)E78 Disorders of lipoprotein metabolism and other lipidaemiasXanthelasmas (Mixed hyperlipidemia)L10-L14 Bullous disordersDermatitis herpetiformisL20 Atopic dermatitis unspecified (1) Eczema (Other atopic dermatitis, unspecified (1) Eczema (Other atopic dermatitis) (2)3L21 Seborrheic dermatitisSeborrheic dermatitis (5)		unspecified)	1
D22 Melanocytic naevi(Melanocytic naevi, unspecified site) (4) 11 Intradermal naevi (Melanocytic naevi, unspecified site) (3) Verrucous naevi (Melanocytic naevi, unspecified site) (2) Hypochromic naevi (Melanocytic naevi, unspecified site) (1) Blue naevi (Melanocytic naevi unspecified site) (1) Blue naevi (Melanocytic naevi unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (2) Dermatofibrome (Benign skin tumor, unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (2) Dermatofibrome (Benign skin tumor, unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (2) Dermatofibrome (Benign skin tumor, unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (1) 3E70 Disorders of aromatic amino-acid metabolismOchronosis (Disorders of tyrosine metabolism)E78 Disorders of lipoprotein metabolism and other lipidaemiasXanthelasmas (Mixed hyperlipidemia)L10-L14 Bullous disordersDermatitis herpetiformisL20 Atopic dermatitis unspecified (1) Eczema (Other atopic dermatitis, unspecified (1) Eczema (Other atopic dermatitis) (2)3L21 Seborrheic dermatitisSeborrheic dermatitis (5)	D10-D36 Benign neoplasms		
naevi, unspecified site) (1) Blue naevi (Melanocytic naevi unspecified site) (1)D23 Other benign neoplasms of skinSebaceous hyperplasia (Benign skin tumor, unspecified site) (2) Dermatofibrome (Benign skin tumor, unspecified site) (1)D23 Other benign neoplasms of skinSumor, unspecified site) (2) Dermatofibrome (Benign skin tumor, unspecified site) (1)B270-E90 Metabolic disordersE70E70 Disorders of aromatic amino-acid metabolismOchronosis (Disorders of tyrosine metabolism)E78 Disorders of lipoprotein metabolism and other lipidaemiasXanthelasmas (Mixed hyperlipidemia)L10-L14 Bullous disordersDermatitis herpetiformisL13 Other bullous disordersDermatitis herpetiformisL20 Atopic dermatitisAtopic dermatitis (Atopic dermatitis, unspecified) (1) Eczema (Other atopic dermatitis, (2)L21 Seborrheic dermatitisSeborrheic dermatitis (5)	D22 Melanocytic naevi	Intradermal naevi (Melanocytic naevi, unspecified site) (3) Verrucous naevi (Melanocytic naevi, unspecified site) (2)) 11
tumor, unspecified site)(2) Dermatofibrome (Benign skin tumor, unspecified site) (1)3E70-E90 Metabolic disorders5E70 Disorders of aromatic amino-acid metabolismOchronosis (Disorders of tyrosine metabolism)1E78 Disorders of lipoprotein metabolism and other lipidaemiasXanthelasmas (Mixed hyperlipidemia)1L10-L14 Bullous disordersDermatitis herpetiformis1L13 Other bullous disordersDermatitis herpetiformis1L20-L30 Dermatitis and eczemaAtopic dermatitis (Atopic dermatitis, unspecified) (1) Eczema (Other atopic dermatitis) (2)3L21 Seborrheic dermatitisSeborrheic dermatitis (5)4		naevi, unspecified site) (1) Blue naevi (Melanocytic naevi unspecified site) (1)	
E70 Disorders of aromatic amino-acid metabolismOchronosis (Disorders of tyrosine metabolism)1E78 Disorders of lipoprotein metabolism and other lipidaemiasXanthelasmas (Mixed hyperlipidemia)1E10-L14 Bullous disordersDermatitis herpetiformis1L13 Other bullous disordersDermatitis herpetiformis1L20-L30 Dermatitis and eczemaL20Atopic dermatitis (Atopic dermatitis, unspecified) (1) Eczema (Other atopic dermatitis) (2)3L21 Seborrheic dermatitisSeborrheic dermatitis (5)3		tumor, unspecified site)(2) Dermatofibrome (Benign skin tumor,	3
metabolism)1E78 Disorders of lipoprotein metabolism and other lipidaemiasXanthelasmas (Mixed hyperlipidemia)1L10-L14 Bullous disordersDermatitis herpetiformis1L13 Other bullous disordersDermatitis herpetiformis1L20-L30 Dermatitis and eczemaAtopic dermatitis (Atopic dermatitis, unspecified) (1) Eczema (Other atopic dermatitis) (2)3L21 Seborrheic dermatitisSeborrheic dermatitis (5)3			
lipidaemiasL10-L14 Bullous disordersL13 Other bullous disordersDermatitis herpetiformisL20-L30 Dermatitis and eczemaL20 Atopic dermatitisL20 Atopic dermatitisAtopic dermatitis (Atopic dermatitis, unspecified) (1)Eczema (Other atopic dermatitis) (2)L21 Seborrheic dermatitis	E70 Disorders of aromatic amino-acid metabolism		1
L13 Other bullous disordersDermatitis herpetiformis1L20-L30 Dermatitis and eczemaAtopic dermatitis (Atopic dermatitis, unspecified) (1)3L20 Atopic dermatitisEczema (Other atopic dermatitis) (2)3L21 Seborrheic dermatitisSeborrheic dermatitis (5)3		Xanthelasmas (Mixed hyperlipidemia)	1
L20-L30 Dermatitis and eczema L20 Atopic dermatitis Atopic dermatitis (Atopic dermatitis, unspecified) (1) Eczema (Other atopic dermatitis) (2) L21 Seborrheic dermatitis	L10-L14 Bullous disorders		
L20 Atopic dermatitisAtopic dermatitis (Atopic dermatitis, unspecified) (1) Eczema (Other atopic dermatitis) (2)3L21 Seborrheic dermatitisSeborrheic dermatitis (5)	L13 Other bullous disorders	Dermatitis herpetiformis	1
L21 Seborrheic dermatitis (5) unspecified) (1) Eczema (Other atopic dermatitis) (2) 3 Seborrheic dermatitis (5)	L20-L30 Dermatitis and eczema		
L21 Seborrheic dermatitis (5)	L20 Atopic dermatitis		
Ashy Dermatitis (1) 6	L21 Seborrheic dermatitis		3
		Ashy Dermatitis (1)	6

 Table 1

 Disease categories, described disease (standard disease), case number (continued)

	disease, case number (continued)	
L25 Unspecified contact dermatitis	Contact dermatitis (Unspecified contact dermatitis, unspecified cause)	6
L28 Lichen simplex chronicus and prurigo	Neurodermatitis (Lichen simplex chronicus) (4)	-
	Prurigo (Other prurigo) (1)	5
L30 Other dermatitis	Pytiriasis alba (1)·	
	Dishydrosis (pompholyx) (1)	2
L40-L45 Papulosquamous disorders		
L40 Psoriasis	Psoriasis	2
L41 Parapsoriasis	PLEVA (Pytiriasis linquenoides	
	et varioliformes acuta) (2)	
	Parapsoriasis (1)	3
L43 Lichen planus	Lichen Planus	1
L50-L54 Urticaria and erythema		
L50 Urticaria	Urticaria (Urticaria, unspecified)	1
L55-L59 Radiation-related disorders of the skin and subc	utaneous tissue	
L56 Other acute changes in the skin due to solar radiation	Actinic leukopathy (Other specified	
	acute skin changes due to ultraviolet	
	radiation)	1
L59 Other disorders of skin and subcutaneous tissue related	(L59.8 Other acute changes in the	
to radiation	skin due to radiation)	1
L57 Other acute changes in the skin due to ionizing radiation	Actinic keratosis	3
	Keratosis pilaris	2
	Dermatoheliosis*	8
	Cuperosis*	1
L60-L75 Disorders of skin appendages		
L63 Alopecia areata	Alopecia areata	1
L64 Androgenic alopecia	Androgenic alopeica	3
L65 Other nonscarring hair loss	Efluvium (1)	
	Telogen Efluvium (1)	2
L70 Acne	Ance (23)	
	Nodule cystic Acne (Other acne) (2)	
	Comedonic acne (Other acne) (1)	
	Pfanasol acne (Other acne) (1)	
	Acne vulgaris (3)	30
L73 Other follicular disorders	Folicullitis (Folicullar disorder unspecified) (1)	
	Cicatricial Acne (Acne keloid) (2)	3
L71 Rosacea	Perioral dermatitis (1) Rosacea (Rosacea, unspecified) (2)	3
		0

Table 1 Disease categories, described disease (standard disease), case number (continued)

		4
L72 Follicular cysts of skin and subcutaneous tissue	Epidermal cyst	1
L80-L99 Other disorders of the skin and subcutaneous t		
L80 Vitiligo	Vitiligo	7
	Melasma (Chloasma) (16)	30
	Ephelide (4	
	Solar Lentigo (Other melanin	
	hyperpigmentation) (10)	
L81 Other disorders of pigmentatio	Seborrheic Keratosis	8
L82 Seborrhoeic keratosis		
L90 Atrophic disorders of skin	Basocelullar scar (1)	
	Acne scar (Scar conditions and	
	fibrosis of skin)(1)	
	Striae (1)	3
L99.0* Amiloidosis of skin	Lichen amiloid (1)	
	Amiloidosis (E85 Amiloidosis) (2)	3
Q20-Q28 Congenital malformations of the circulatory sy	stem	
Q27 Other congenital malformations of peripheral vascular	Vascular Malformation (Congenital	
system	malformation of peripheral vascular	
	system, unspecified)	1
Q80-Q89 Other congenital malformations		
Q82 Other congenital malformations of the skin	Poikiloderma (Other specified	
	congenital malformations of the skin)	
Q84 Other congenital malformations of integument	Pachyoniquia Congenita (Enlarged and	ł
	hypertrophic mails)	1
	Achrochordons	1
	Postinflammatory pigmentation	1
	Atopic diathesis	1
	Granulomma anulare figurate erythem	a 1

information to support precision diagnostic processes like biopsies. Technically, these studies are performed in diverse conditions affecting their quality. In the studies of low concordance, diverse obstacles like low quality photography due to lack of training and experience were evidenced. This is further potentiated due to the lack of adequate digital dermatologic photography protocols that involve important aspects like scenography and illumination. Other limitations identified were the lack of education and inertia of the potential users, as well as the inconvenience generated by some users. On the other hand, the studies with high concordance course with the implementation of good teledermatology practices go from image acquisition to precise and reliable information compilation by means of the electronic health record (EHR). The relevance of the latter aspect must be highlighted; Blum *et al.*¹² states an increase in diagnostic reliability when dermatologists obtain more information in addition to photographs. In our case, the concordance values obtained were possible in part due to specific information acquisition in a standard and precise manner during the consultations.

The «face to face» diagnosis given by the teleexpert and the control dermatologist (CP) was of 77.9%, concordance value in agreement with the studies performed by Whited *et al.*¹² and Lim *et al.*¹² in which percentages of 54% and 79% were respectively obtained. Attention must be drawn to the fact that this important C 01P-02T

CIO

	ance levels for each one the dermatologists	
Modality	% (n)	
CIO1	86.6 (172)	
CIO2	80.8 (172)	
CP	77.9 (172)	
СТ	76.1 (172)	
C 01T-02P	79.6 (172)	

Table 2

CIO1: Teleexpert intraobserver concordance; CIO2: Dermatologist intraobserver concordance; CP: present interobserver concordance; CT: interobserver telediagnostic concordance; CO1T-O2P: teleexpert telediagnosis - presential dermatologist concordance; CO1P-O2T: presential teleexpert-dermatologist telediagnosis concordance; CIO: interobserver concordance when CIO1=CIO2

77.3 (172)

77.9 (172)

concordance measure, not frequently analyzed in similar teledermatology studies, confirms that albeit «face to face» consultation being the standard modality in healthcare services, physicians do not carry out examinations with perfect reliability or exactness, with

tendency not coincide, to a certain point, in the independent diagnosis of the modality¹². The telediagnosis emitted by the teleexpert and the control dermatologist (CT) was of 76.1%. This percentage is valid according to the studies¹² in which a range between 44% and 95% is obtained. Emphasis must be made on that for the previous concordance values, the diagnostic category of adnexal disease were highest. In contrast, the CT value presented for eczema and dermatitis was relatively low. This may suggest that dermatologic photography protocols and EHR need specific emphasis in these categories in order to obtain precise information. Finally, an interobserver concordance value based on the intraobserver concordance value of 77.9% was obtained. No evidence was found on studies that evaluated this concordance, but it is clear that the teledermatologic tool presents a basic effectiveness that is susceptible of improvement.

Patient satisfaction with respect to the service of teledermatology was high. The understanding of the information, the quality in the healthcare service and time duration were qualified as excellent in an average of 92.5%, confirming the great potential for acceptance that teledermatology has in the population. Diverse studies that focused on this issue offer general satisfaction

Та	able 3		
Concordance	level	by	category

Modality	L20-L30	L60-L75 Disorders of	L80-L99 Other disorders of the
,	Dermatitis and Eczema	skin appendages	skin and subcutaneous tissue
	Kappa (IC 95%)	Kappa (IC 95%)	Kappa (IC 95%)
CIO1	0.9884 (n=22) (0.85-1)	1 (n=43)	0.9629 (n=37) (0.8912-1)
CIO2	0.8965 (n=22)	0.9403 (n=43)	0.9295 (n=37)
	(0.7615-1)	(0.8609-1)	(0.8345-1)
СР	0.7424 (n=22)	0.8450 (n=43)	0.7458 (n=37)
	(0.5480-0.9368)	(0.7254-0.9646)	(0.5860-0.9057)
СТ	0.6952 (n=22)	0.8762 (n=43)	0.7483 (n=37)
	(0.4987-0.8916)	(0.7668-0.9856)	(0.5907-0.9059)
C 01T-02P	0.7939 (n=22)	0.8504 (n=43)	0.7413 (n=37) (
	(.6169-0.9709)	(0.7229-0.9779)	0.5790-0.9035)
C 01P-02T	0.7089 (n=22)	0.8821 (n=43)	0.7463 (n=37)
	(0.5175-0.9002	(0.7621-1)	(0.5872-0.9054)
CIO	0.81 (n=22)	0.88 (n=43)	0.78 (n=37)

Variable	Conceptual definition	Indicators (%)
Information understanding	Correct comprehension of the documents:	
	A. Information on services and telemedicine	5 (93.2)
	modality	4 (6.8)
	B. Informed consent	5 (94.5)
		4 (5.5)
Attention	Personalized service and telemedicine consult	5 (97.3)
	modality	4 (2.7)
Time	Time duration of the telemedicine consult	5 (84.9)
		4 (13.7)
		3 (1.4)

Table 4 Patient satisfaction

	Table	5	
Technical	evaluation.	Medical	resident

Variable	Conceptual definition	Indicators (%)
Speed	Time the system takes to:	
	A. Show information	5 (86.7)
		4 (12.0)
		2 (1.3)
	B. Load pictures	5 (61.3)
		4 (26.7)
		3 (8.0)
		2 (1.3)
		1 (2.7)
Stability	A. Correct delivery of required information	5 (97.3)
		4 (2.7)
	B. Constant working	5 (90.7)
		4 (8.0)
		2 (1.3)
Consult coordination	Integration of the system to the consult process:	
	A. Compatibility between the steps to follow during the	5 (93.3)
	consult and those necessary to enter the information in the system	4 (6.7)
	B. Ease of image capture	5 (89.3)
		4 (10.7)
	C. Ease of communication for assessment reception	5 (88.0)
		4 (12.0)

Variable	Conceptual definition	Indicators (%)
eed	Time the system takes to:	
	A. Show information	5 (36.4)
		4 (50.9)
		3 (12.7)
	B. Load pictures	5 (29.1)
		4 (45.5)
		3 (23.6)
		1 (1.8)
ability	A. Correct delivery of required information	5 (41.8)
		4 (58.2)
		5 (50.9)
	B. Constant working	4 (47.3)
	-	1 (1.8)

Table 6Technical evaluation. Teleexpert

results that range between 42% and 93%^{11,12,16} in a system as the one evaluated. In relation to the teleexpert's and the residents' satisfaction, the system had a suboptimal behavior with respect to speed. In this variable, the Internet connection quality played a determining role, given that on occasions the service was deficient, producing system failures and consequently general failures. It must be made clear that the medical residents, persons who totally interacted with the system, qualified the system as excellent (86.6%). With respect to system stability, both medical residents and the teleexpert qualified the system as excellent (70.2%). The coordination with the consultation using the teledermatology system was qualified as excellent by the medical residents (90.2%). These values are comparable to few studies on the subject suggesting that general satisfaction of teledermatologist with these systems is high, with respect to quality $(70\%^{11})$ and feasibility $(93\%^{12})$ of the teleconsultations.

The values presented must be analyzed from the activities and methodologies point of view, which may be better developed. Even though the concordance values are high in comparison to similar studies, the quality of images, the ideal conditions for photography, the lack of a photographic protocol, the impossibility of some activities like palpation, the lack of information supplied to the teleexpert and the difficulties to completely fulfill the clinical records were key determinants in the adequate

application of these studies.

In some of the studies analyzed, professional photographers, research assistants and trained technicians, using photographic adjustments, specific protocols and software images, acquired the dermatologic images¹². This generates ideal quality conditions that are on occasion difficult to attain. Regarding to image quality, the studies analyzed work with sizes that vary from 640x480 to 1200x1800^{5,10,12}. In the present study, a resolution of 1296 x 864 was used, which fully satisfies the minimum (768x512) defined by Bittorf et al.²² Using high resolution images increases the quality but implies greater storing size, longer transmission times and need for connections to high speed internet¹². This leads to the analysis of dermatology as an area of high impact imaging that must use standards like DICOM (Digital Imaging and Communication in Medicine) and high computation technologies like grid computing that allow access, analysis, protection and exchange of great quantities of geographically distributed information under platforms of high speed communications like RENATA (Red Nacional Académica de Alta Tecnología). Likewise, the need for adequate photography protocol development using professional cameras that allow for macro close up pictures is of great priority. On occasions, it was necessary to obtain close up pictures that provided better information of the lesion from various focal points. This took time due to the light conditions, technical adjustments

of the camera and correct visualization in the camera but low sharpness when downloaded. The lack of dermatologic digital photography protocols in which controlled environments for photography acquisition that are adequate for the phenotype of our region must be added to these limitations.

In relation to the clinical information, the system possesses a structure of standardized information following defined patterns by the Dermatologic Center CES Sabaneta. However, on occasions, the teleexpert received better information when in direct contact with the patient having that the latter did not mention or completely expose his/her clinical condition. Additionally, for some dermatologic manifestations like dermatofibromas and panniculitis, among others, the descriptive information is not a good substitute for the information that may be acquired by means of a physical examination, allowing for evaluation of contour, texture and other important aspects. For this, the implementation of information standards in structured reports as DICOM SR (Structured Reporting) and HL7 CDA (Health Level 7-Clinical Document Architecture) is necessary. Experience has demonstrated that the use of these documents to report clinical information reduce the ambiguity of the reports in natural language and increases the precision, clarity and value of the clinical documents²³.

The present study permitted the establishment of the viability and reliability of a «store and forward» or asynchronous teledermatology system based on open source technology. The acceptance of this system is supported by both the dermatologists and residents involved, as well as by the population studied. Additionally, the outline is set for future work in the development of a photographic protocol, implementation of DICOM²⁴ and HL7 and use of computational grids²⁵.

For this reason, the dermatologic care service via telemedicine in remote locations with high consult incidence and where a constant service is not available is a reality that presents great advantages for the patient, who will receive specific and prompt attention without long awaiting periods; the medical staff, who will have to travel less to provide the service and obtain education; and finally, the healthcare institutions that could count on accessible and affordable technology to extend their services in high market zones. It is recommended to continue the evaluation processes of these systems with the objective of developing high quality evidence like clinical controlled studies. Lastly, it is evidenced that in the Colombian scenario, teledermatology may be an appropriate tool for skin cancer detection, having that for 1999 this was the third chief consult based on the information from the National Cancer Institute²⁶.

Interest conflict. The authors declare that there are no interest conflicts in this manuscript.

ACKNOWLEDGEMENT

Carlos Ruiz was financed by the Administrative Department of Science, Technology and Innovation (COLCIENCIAS), the Escuela de Ingeniería, Universidad de Antioquia and the Universidad CES.

REFERENCES

- 1. Haux R, Ammenwerth E, Herzog W, Knaup P. Health care in the information society. A prognosis for the year 2013. *Int J Med Inform.* 2002; 66: 3-21.
- Berghout RM, Eminovic N, de Keizer N, Birnie E. Evaluation of general practitioner's time investment during a store-andforward teledermatology consultation. *Int J Med Inform.* 2007; 76 (Suppl 3): 384-91.
- 3. Eedy DJ, Wootton R. Teledermatology: a review. Br J Dermatol. 2001; 144: 696-707.
- Ruiz C, Zuluaga A, Trujillo A. Telemedicina: introducción, aplicación y principios de desarrollo. *Rev CES Med.* 2007; 21: 77-93.
- Lepe V, Moncada B, Castanedo-Cázares JP, Martínez RA, Mercado-Ceja SM, Gordillo-Moscoso A. Primer estudio de teledermatología en México. Una nueva herramienta de salud publica. *Gac Med Mex.* 2004; *140:* 23-6.
- 6. Knol A, van den Akker W, Damstra RJ, de Haan J. Teledermatology reduces the number of patient referrals to a dermatologist. *J Telemed Telecare*. 2006; *12*: 75-8.
- Casanova Seuma JM, Buti Solé M, Martí Laborda RM, Baradad Brusau M, Riba Torrecilla D, Freixanet Pedrós P. Teledermatología. *Med Cutan Iber Lat Am.* 2005; 33: 53-64.
- 8. Ferguson J. How to do a telemedical consultation. *J Telemed Telecare*. 2006; *12*: 220-7.
- 9. Pak HS. Teledermatology and teledermatopathology. *Semin Cutan Med Surg.* 2002; *21:* 179-89.
- Tait C, Clay C. Pilot study of store and forward teledermatology services in Perth, Western Australia. *Australas J Dermatol.* 1999; 40: 190-3.
- 11. Whited J. Teledermatology research review. *Int J Dermatol.* 2006; *45:* 220-9.
- 12. Eminonovic N, de Keizer NF, Bindels PJE. Hasman A. Maturity of teledermatology evaluation research: a systematic literature review. *Br J Dermat.* 2007; *156:* 412-9.
- Browns IR, Collins K, Walters SJ, McDonagh AJG. Telemedicine in dermatology: a randomized controlled trial (executive summary). *Health Technol Asses*. 2006; *10*:1-6.

- Jaramillo F, Santacoloma G, Montoya JH, Arbeláez M. Concordancia entre diagnóstico presencial y telediagnóstico en pacientes dermatológicos. *Acta Med Colomb.* 2003; 28: 11-4.
- 15. Romero G, García M, Vera E, Martínez C, Cortina P, Sánchez R, *et al.* Resultados preliminares de DERMATEL: estudio aleatorizado prospectivo comparando modalidades de teledermatología síncrona y asíncrona. *Actas Dermosifiliogr.* 2006; *97:* 630-6.
- Collins K, Walters S, Browns I. Patient satisfaction with teledermatology: quantitative and qualitative results from a randomized controlled trial. *J Telemed Telecare*. 2004; *10*: 29-33.
- BVS (Biblioteca Virtual en Salud). Descriptores en ciencias de la salud [sede Web]. [fecha de acceso enero 27 de 2009]. Disponible en: http://decs.bvs.br/E/homepagee.htm
- Edison KE, Ward DS, Dyer JA, Lane W, Chance L, Hicks LL. Diagnosis, diagnostic confidence, and management concordance in live-interactive and store-and-forward teledermatology compared to in-person examination. *Telemed J E Health.* 2008; 14: 889-95.
- Trindade MA, Wen CL, Neto CF, Escuder MM, Andrade VL, Yamashitafuji TM, et al. Accuracy of store-and-forward diagnosis in leprosy. J Telemed Telecare. 2008; 14: 208-10.
- Ferrandiz L, Moreno-Ramírez D, Nieto-García A, Carrasco R, Moreno-Álvarez P, Galdeano R, *et al.* Teledermatology -

based presurgical management for nonmelanoma skin cancer: a pilot study. *Dermatol Surg.* 2007; *33:* 1092-98.

- 21. Di Stefani A, Zalaudek I, Argenziano G, Argenziano G, Chimenti S, Soyer HP. Feasibility of a two-step teledermatologic approach for the management of patients with multiple pigmented lesions. *Dermatol Surg.* 2007; *33:* 686-92.
- 22. Bittorf A, Fartasch M, Schuler G, Diepgen T. Resolutions requirements for digital images in dermatology. J Am Acad Dermatol. 1997; 37 (2 Pt 1): 195-8.
- 23. Hussein R, Engelmann U, Schroeter A, Meinzer HP. DICOM Structured Reporting: Part 1 Overview and characteristics. *Radiographics.* 2004; 24: 891-6.
- 24. García A, Ruiz C, Valencia E, Ramírez JC, Peláez A, Montoya E, et al. Representación de objetos DICOM en XML para uso en repositorios distribuidos. Memorias III Congreso Colombiano de Bioingeniería e Ingeniería Biomédica [CD-ROM], 2008. Junio 4-6; Pereira, Colombia; 2008.
- 25. García A, Ruiz C, Valencia E, Ramírez JC, Peláez A, Montoya E, et al. Modelación de la plataforma Mantis-GRID para la gestión e integración de repositorios distribuidos de imágenes médicas. Memorias III Congreso Colombiano de Bioingeniería e Ingeniería Biomédica [CD-ROM], 2008. Junio 4-6; Pereira, Colombia. 2008.
- 26. Duarte-Agudelo J, Garnica Y. *Cáncer de piel: generalidades.* Bogotá: Liga Colombiana Contra el Cáncer; 2008. p.19.